Alert detail
LCD L40226: MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in Cancer — CGS
What changed
CGS final LCD sets NGS-alternative molecular panel rules for cancer therapy
Who’s affected: Oncology billing teams · Effective: October 12, 2026
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 10 billing codes.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.